CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) and Arcus Biosciences (NYSE:RCUS – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations.
Risk and Volatility
CollPlant Biotechnologies has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Arcus Biosciences has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500.
Institutional and Insider Ownership
21.7% of CollPlant Biotechnologies shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 9.6% of CollPlant Biotechnologies shares are owned by insiders. Comparatively, 7.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CollPlant Biotechnologies | 1 | 1 | 0 | 0 | 1.50 |
| Arcus Biosciences | 1 | 3 | 10 | 0 | 2.64 |
CollPlant Biotechnologies presently has a consensus target price of $120.00, indicating a potential upside of 2,531.58%. Arcus Biosciences has a consensus target price of $38.30, indicating a potential upside of 51.40%. Given CollPlant Biotechnologies’ higher probable upside, analysts clearly believe CollPlant Biotechnologies is more favorable than Arcus Biosciences.
Profitability
This table compares CollPlant Biotechnologies and Arcus Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CollPlant Biotechnologies | -683.68% | -218.81% | -139.28% |
| Arcus Biosciences | -393.16% | -89.54% | -45.61% |
Valuation and Earnings
This table compares CollPlant Biotechnologies and Arcus Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CollPlant Biotechnologies | $2.37 million | 2.77 | -$11.49 million | ($14.50) | -0.31 |
| Arcus Biosciences | $247.00 million | 13.04 | -$353.00 million | ($3.90) | -6.49 |
CollPlant Biotechnologies has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Summary
Arcus Biosciences beats CollPlant Biotechnologies on 9 of the 14 factors compared between the two stocks.
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.
About Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
